The cost-effectiveness of 23-valent pneumococcal vaccine in Catalonia, Spain

被引：0
|
作者：
Plans-Rubió, P [1 ]
机构：
[1] Dept Sanitat Catalonia, Barcelona, Spain
来源：
VALUE IN HEALTH | 2003年 / 6卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)61921-3
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：754 / 754
页数：1
相关论文
共 50 条
  • [31] A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan
    Jiang, Yiling
    Yang, Xiaoqin
    Taniguchi, Kazuko
    Petigara, Tanaz
    Abe, Machiko
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 687 - 697
  • [32] Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
    Masuda, Toshihiro
    Akamatsu, Taisuke
    Nakatani, Eiji
    Tamura, Kanami
    Takahashi, Shingo
    Tanaka, Yuko
    Watanabe, Hirofumi
    Endo, Yoshinari
    Suzuki, Takahito
    Noguchi, Rie
    Saigusa, Mika
    Yamamoto, Akito
    Shishido, Yuichiro
    Akita, Takefumi
    Morita, Satoru
    Asada, Kazuhiro
    Shirai, Toshihiro
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [33] Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine
    Zielen, S
    Bühring, I
    Strnad, N
    Reichenbach, J
    Hofmann, D
    INFECTION AND IMMUNITY, 2000, 68 (03) : 1435 - 1440
  • [34] Invasive pneumococcal disease epidemiology and effectiveness of 23-valent pneumococcal polysaccharide vaccine in Alaska Native adults
    Singleton, Rosalyn J.
    Butler, Jay C.
    Bulkow, Lisa R.
    Hurlburt, Debby
    O'Brien, Katherine L.
    Doan, William
    Parkinson, Alan J.
    Hennessy, Thomas W.
    VACCINE, 2007, 25 (12) : 2288 - 2295
  • [35] Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations
    Wang, Yang
    Li, Jingxin
    Wang, Yuxiao
    Gu, Wei
    Zhu, Fengcai
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (04) : 1003 - 1012
  • [36] Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults
    Benin, AL
    O'Brien, KL
    Watt, JP
    Reid, R
    Zell, ER
    Katz, S
    Donaldson, C
    Parkinson, A
    Schuchat, A
    Santosham, M
    Whitney, CG
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01): : 81 - 89
  • [37] The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study
    Ding, Hanyue
    Huang, Junjie
    Ngai, Chun Ho
    Sun, Qingjie
    Kwok, Kin-On
    Wang, Harry H. X.
    Chong, Marc
    Wong, Martin C. S.
    VACCINE, 2022, 40 (09) : 1282 - 1288
  • [38] Cost-Effectiveness Analysis of Universal Vaccination of Adults Aged 60 Years with 23-Valent Pneumococcal Polysaccharide Vaccine versus Current Practice in Brazil
    de Soarez, Patricia Coelho
    Christovam Sartori, Ana Marli
    Freitas, Angela Carvalho
    Nishikawa, Alvaro Mitsunori
    Dutilh Novaes, Hillegonda Maria
    PLOS ONE, 2015, 10 (06):
  • [39] Safety of 23-Valent Pneumococcal Vaccine in Rheumatoid Arthritis Patients
    Naumtseva, Marina S.
    Belov, Boris S.
    Tarasova, Galina M.
    Karateev, Dmitriy E.
    Luchikina, Elena E.
    Muravyev, Yury V.
    Alexandrova, Elena N.
    Novikov, Alexander A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (04) : S21 - S21
  • [40] SAFETY AND IMMUNOGENICITY OF 23-VALENT PNEUMOCOCCAL VACCINE IN SLE PATIENTS
    Tarasova, G.
    Belov, B.
    Bukhanova, D.
    Soloviev, S.
    Aseeva, E.
    Popkova, T.
    Cherkasova, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1061 - 1061
12345